MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX)

141 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q4 2024.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 63.2M shares of 63.5M outstanding shares and own 99.61% of the company stock.
Largest 10 shareholders include BVF INC/IL (19.8M shares), Cormorant Asset Management, LP (8.49M shares), FMR LLC (6.34M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.34M shares), Avoro Capital Advisors LLC (2.77M shares), CITADEL ADVISORS LLC (2.19M shares), Paradigm Biocapital Advisors LP (1.77M shares), GOLDMAN SACHS GROUP INC (1.67M shares), Holocene Advisors, LP (1.59M shares), and WESTFIELD CAPITAL MANAGEMENT CO LP (1.31M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.